Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BMS-986224 in Renal Impairment
NCT03634969Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-986224 in heart failure (HF) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 11 days, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration up to 11 days and 10 more. Started Aug 2018; status: completed.
02
Drugs
BMS-986224
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03634969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634969.